Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
Year: 2011
Type: article
Abstract: Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoints that better reflect long-term outcome may be more meaningful. We discuss potential endpoints and consider why the same measures may not be appropriate for both idiopathic PAH and PAH-SSc due to inherent differences in clinical outcome and management strategies of these two forms of PAH. Failure to take this into account may compromise progress in managing PAH in SSc.
Source: Arthritis Research & Therapy
DOI: 10.1186/ar3346
Institutions: The Royal Free Hospital, University College London, German Rheumatism Research Centre, University of California, Los Angeles, Université Paris-Sud, Hôpital Antoine-Béclère, Goethe University Frankfurt, Medical University of Białystok, University of Florence, DRK Kliniken Berlin, Technische Universität Dresden, University of California San Diego, University Hospital Zurich
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,690
OpenAlex ID: W2133116831